Walbrook PR appointed by Lipoxen plc
November 17 2010 - 2:00AM
UK Regulatory
TIDMLPX
RNS Number : 2963W
Lipoxen PLC
17 November 2010
Walbrook PR appointed by Lipoxen plc as financial PR and IR advisor
Lipoxen (AIM: LPX.L), ('Lipoxen' or 'the Company') a bio-pharmaceutical company
specialising in the development of high-value differentiated biologicals,
vaccines and siRNA delivery, is pleased to announce the appointment of Walbrook
PR Ltd as its financial PR and IR advisor.
For further information, please contact:
Enquiries
+-----------------------------------+-------------------------------+
| Lipoxen plc | +44 (0)20 7389 5015 |
+-----------------------------------+-------------------------------+
| M. Scott Maguire, Chief Executive | |
| Officer | |
+-----------------------------------+-------------------------------+
| | |
+-----------------------------------+-------------------------------+
| Singer Capital Markets (nominated | +44 (0)20 3205 7500 |
| adviser) | |
+-----------------------------------+-------------------------------+
| Jeff Keating / Claes Spång | |
+-----------------------------------+-------------------------------+
| | |
+-----------------------------------+-------------------------------+
| Walbrook PR Ltd | +44 (0)20 7933 8780 |
+-----------------------------------+-------------------------------+
| Paul McManus (Media Relations) | paul.mcmanus@walbrookpr.com |
+-----------------------------------+-------------------------------+
| Paul Cornelius (Investor | paul.cornelius@walbrookir.com |
| Relations) | |
+-----------------------------------+-------------------------------+
| | |
+-----------------------------------+-------------------------------+
About Lipoxen
Lipoxen plc is a biopharmaceutical company focused on the development of new and
improved biologic drugs and vaccines. Lipoxen has three proprietary patented
technology platforms:
1) PolyXen - for extending the efficacy and half life of biologic drugs
2) ImuXen - for creating new vaccines and improving existing vaccines
3) SiRNAblate - for the delivery of siRNA
Lipoxen's technology is designed to improve the efficacy, safety, stability,
biological half-life and immunologic characteristics of its products.
Lipoxen has multiple drug and vaccine programmes in development. Two products
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes
vaccines against HIV, influenza and malaria and an exclusive license deal with
Baxter Healthcare for blood coagulation drugs.
The Company has a low-risk business model and out-licenses its proprietary
technologies to biopharmaceutical companies that have strong manufacturing and
marketing capabilities. Lipoxen currently has commercial agreements with some
of the world's leading biotechnology and pharmaceutical companies including
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and
management led the GBP2.9 million fundraising that the Company announced in May
2009. This fundraising was followed up by a GBP1.2 million placing in April 2010
which was led by the Company's management team.
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock
Exchange under the ticker symbol LPX. More information can be found at the
Company's website: www.lipoxen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRGMMMMNVFGGZM
Lipoxen (LSE:LPX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jan 2024 to Jan 2025
